MGTX:NASDAQ, MeiraGTx Holdings plc

MGTX stock overview

MeiraGTx Holdings plc (MGTX:NASDAQ) closed at $9.18 on November 13, 2026, up 4.44% on the day. The stock trades 40.2% below its 52-week high of $15.35 and 38.7% above its 52-week low of $6.62. Over the past year, it gained 12.1%. MeiraGTx Holdings plc is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).

Key figures

Price

$9.18

Day change

+4.44%

Volume

731,921

Average volume

839,900

Market cap

881M+

52-week range

$6.62 – $15.35

50-day average

$10.81

200-day average

$10.37

Price action over the past year

In 252 trading sessions since November 13, 2025, MGTX closed higher on 119 days (47%). Its best day was April 14, 2026 (+17.24%) and its worst was April 16, 2026 (-15.73%). The stock moved 10% or more in a single session 2 times. It opened at least 5% above the previous day's high 1 time.

Recent signals

• Nov 13, 2026: Down 33.3% over 90 days, from $13.77 (Dips & Crashes scanner)
• Nov 13, 2026: Trading sideways between $8.51 and $9.68 over 14 days (Sideways scanner)
• Nov 12, 2026: News catalyst: Earnings (News Catalysts scanner)

MGTX news

• Nov 12, 2026: MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Misses Revenue Estimates
• Nov 12, 2026: MeiraGTx Reports Third Quarter 2026 Financial and Operational Results
• Nov 11, 2026: Alpha Cognition Inc. (ACOG) Reports Q3 Loss, Beats Revenue Estimates
• Nov 10, 2026: Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Misses Revenue Estimates
• Oct 27, 2026: MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting
• Sep 23, 2026: MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
• Aug 26, 2026: Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical

About MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a clinical stage gene therapy company. Its pipeline products include AAV-CNGB3, AAV-CNGA3. AAV-UPF1, West AMD, Dry AMD, and others. Geographically, the company generates a majority of its revenue from the United Kingdom.

Similar stocks

• SLDB:NASDAQ
• DBVT:NASDAQ
• NVAX:NASDAQ
• ENTX:NASDAQ
• RGNX:NASDAQ
• MESO:NASDAQ
• FENC:NASDAQ
• BCRX:NASDAQ

Find more stocks like MGTX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.